Hadasit Medical Research Services and Development Ltd.

Enzo Therapeutics, Inc.

Other

Exalenz Bioscience Ltd.

Ben-Gurion University of the Negev Research and Development Authority

Oberon Sciences Ilan Ltd.

Alcobra Ltd.

Northwestern University

Immuron Limited

The Brigham and Women's Hospital, Inc.

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Protalix Ltd.

Gavish-Galilee Bio Applications Ltd.

Aristotle University of Thessaloniki

Enzo Biochem, Inc.

Yaron Ilan

Eran Elinav

Ami Ben-Ya'Acov

Avraham Hershkowitz

Smadar Cohen

Ilan Ben-Oren

Maya Margalit

Eyal Shteyer

Gil Guggenheim

Gadi Lalazar

Richard B Silverman

Ilan Ben Oren

Dalia Megiddo

Rina Yamin

Meir Mizrahi

Shimon Amselem

Hejun Lu

Ari Zimran

Dean Nahman

Yaron Bar-Ilan

Tomer Adar

Shmuel Chen

Gur Megiddo

Ehud Zigmond

Tsiona Elkayam

Elazar Rabbani

Elazar S Rabbani

James J Donegan

Howard L Weiner

Raphael Mechoulam

Yoseph Shaaltiel

Dean L Engelhardt

Michael Hayden

Tali Kizhner

Arie Dagan

Uri Hanania

Josef Mograbi

Elliot Berry

Yosefa Avraham

Svetlana Gingis-Velitski

Tami Ariel

Yossi Dagon

Dan Levanon

Jayanta Roy-Chowdhury

Refael Aharon

Einat Amit-Romach

Iddo Magen

Nicholas Grigoriadis

Theofilos Poutachidis

Ami Ben-Yaakov

Eli Kaplan

Ofer Danai

Dario Vertnik

Mori Arkin

Mira Kremer

Israel Gotsman

Tahel Ilan Ber

Doina Cosma Roman

Ami Ben-Ya'acov

Gad Lalazar

The disclosure provides methods for improving the function of systems regimens, devices by identifying, quantifying, and implementing at least one inherent variability pattern which is based on patterns learned from a specific subject or from other subjects including subject's variability patterns, such as, DNA, genes, nucleic acids, RNA, proteins, cells, organs, biological pathway(s), or whole body variability. There are provided herein devices, systems, and methods for real time or delayed altering of the parameters of system's regimens, for improving biological systems functions. Any system used by humans, or affect human function, wherein the parameters are updated using inherent variabilities signatures with and without other individualized patterns from a subject or from other subjects, can increase the accuracy and efficacy of the system for achieving the desired goal. Output parameters are continuously, semi continuously, or conditionally being updated based on measurements and inputs provided to a compute circuitry configured to facilitate closed loop machine learning capabilities.

Identifying and quantifying individualized variability-patterns and implementing them for improved efficacy of systems

There are provided herein a system and a computer implemented method for preventing, mitigating or treating partial/complete loss of effect of one or more drugs or medical devices administered to or used by a subject in need thereof due to adaptation, tolerance, and/or tachyphylaxis, and/or for preventing, mitigating or treating non-responsiveness to one or more drugs, maximizing therapeutic effect of one or more drugs, or for improving target or non-target organ/organs response to therapy, the system/method include (processing circuit configured to): receiving a plurality of physiological or pathological parameters of the subject; applying a machine learning algorithm on the plurality of physiological or pathological parameters; and determining a subject-specific administration regimen of a drug or a medical treatment, wherein the administration regimen comprises drug administration parameters, cell/tissue/organ stimulation parameters, adjuvant parameters or any combination thereof; wherein the administration regimen is irregular.

Subject-specific system and method for prevention of body adaptation for chronic treatment of disease

The invention provides methods and systems for the treatment and diagnosis of pathologic disorders by modulating a physiological state of a target biological entity via exposure of the target entity to a single or a plurality of triggered entities and for transferring of information in a non-direct way and as part of virtual reality interactive environment.

Methods and systems for modulating physiological states between biological entities

A device for detection of internal bleeding in a patient's body is provided. An optical interface for transmitting IR light through an area of a skin of a patient and to collect IR light from the area of the skin, is provided. In some embodiments the optical interface includes one or more delivery components and one or more collection components. The delivery component includes a plurality of first optical channels configured to transmit the IR light through a plurality of respective first sub-areas on the area of the skin, into an internal layer of the body. The collection component includes a plurality of second optical channels, configured to collect IR light from a plurality of respective second sub-areas on the area of the skin.

Devices and methods for detection of internal bleeding and hematoma

A gastrointestinal stimulation devices including a random stimulation delivery mechanism(s), configured to provide stimuli to a bodily tissue in a vicinity of the stimulation capsule, the provided random stimuli being characterized by a stimulation parameter, and a control circuitry in communication with said physical stimulation delivery mechanism, and configured to set and alter the stimulation parameter non-systematically, thereby altering the characterization of the stimuli provided to the bodily tissue. The algorithm may be patient tailored, and may have a learning machinery which responds to data being received from the patient.

Devices for gastrointestinal stimulation and uses thereof

Methods of treating liver diseases are provided. Accordingly there is provided a method of treating a liver disease selected from the group consisting of fatty liver disease and chronic liver rejection in a subject in need thereof, wherein said liver disease is not associated with genetic alpha-1 anti-trypsin (AAT) deficiency, the method comprising administering to the subject a therapeutically effective amount of AAT.

Alpha-1 anti-trypsin for treating liver diseases

There is provided a method of evaluating a liver condition of a subject, the method includes computing a fluctuation parameter from a liver breath test based on at least one of a percentage dose recovery (PDR) curve and a delta over baseline (DOB) curve of an isotope labeled methacetin, or a salt or a derivative thereof, and evaluating at least one liver condition of the subject, based at least on the fluctuation parameter. There is provided herein a method of evaluating a liver condition of a subject, the method includes computing a hepatic impairment score based at least on a breath test related parameter and on a demographic parameter.

Breath test device and method

Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering from type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.

Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine

The present disclosure provides systems, devices and methods for providing abdominal or any other organ stimulation for affecting a physiological change, wherein the stimulation parameters are continuously, semi continuously, or conditionally being updated based on measurements and inputs provided to a computer circuitry configured to facilitate machine learning capabilities.

Closed loop organ stimulation

The present invention relates to methods for treating psoriasis and other indications by inhibiting leptin activity.

Methods for treating psoriasis

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

Glucocerebroside treatment of disease

A vitamin D2-enriched biomass of an edible fungus, extracts and compositions thereof are provided, for use in delaying onset of, treating, ameliorating or protecting from an immune-related or inflammatory related disease, disorder or condition, wherein the level of vitamin D2 in said biomass is at least 80 IU/gr.

Extracts of edible fungi enriched in vitamin D and compostions thereof and their use in the treatment of immune-related disorders

This application describes a method of delivering a TNF antagonist molecule, in a biologically active form, to a subject in need thereof, the method comprising, orally or mucosally administering to the subject a therapeutically effective amount of a TNF antagonist molecule. This application further describes a method of treating, preventing or reducing liver diseases, the method comprising, administering to the subject a therapeutically effective amount of a TNF antagonist molecule.

Methods for treating or reducing liver diseases by administering oral composition comprising TNF receptor fusion proteins

Compositions comprising an alginate, a source of sodium ions and a carrier (e.g., a pharmaceutically acceptable carrier), which are characterized by reduced association of the alginate chains and hence by at least one of: (i) a zeta potential weaker than &#x2212;25 mV, at a concentration of 0.5% (w/v) alginate in the carrier; and (ii) a diffusion coefficient of at least 10cm/second, at a concentration of 0.5% (w/v) alginate in the carrier, are disclosed. Also disclosed are uses of the composition and methods utilizing the composition for treating inflammatory bowel disease; liver damage, diseases and disorders, for treating a medical condition treatable by a hepatotoxic agent and for reducing or preventing liver damage, including liver damage caused by a hepatotoxic agent.

Alginate compositions and uses thereof

This invention relates to methods and compositions for treating fibrosis, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations. In particular, the invention relates to methods and compositions for the treatment of liver fibrosis and/or lung fibrosis. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.

Anti-LPS enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis

Growing community of inventors

Jerusalem, Israel

Yaron Ilan